Scinai Immunotherapeutics (SCNI) Interest & Investment Income (2020 - 2024)

Scinai Immunotherapeutics has reported Interest & Investment Income for 3 years, with the latest figure at $12.9 million in Q3 2024.

• Quarterly Interest & Investment Income rose 347.17% year-over-year to $12.9 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $3.9 million (changed N/A YoY) and the FY2023 annual result came in at $9000.0, down 99.83% from the prior year.
• Interest & Investment Income advanced to $12.9 million in Q3 2024 per SCNI's latest filing, from -$3.7 million in the prior quarter.
• Over five years, Interest & Investment Income peaked at $12.9 million in Q3 2024 and troughed at -$5.2 million in Q3 2023.
• A 3-year average of $980500.0 and a median of -$1.9 million in 2020 frame the typical range for Interest & Investment Income.
• The widest YoY moves for Interest & Investment Income: up 347.17% in 2024, down 347.17% in 2024.
• Over 3 years, Interest & Investment Income stood at -$40000.0 in 2020, then tumbled by 9160.0% to -$3.7 million in 2023, then soared by 447.6% to $12.9 million in 2024.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $12.9 million, -$3.7 million, and -$5.2 million for Q3 2024, Q4 2023, and Q3 2023 respectively.